Enveric Biosciences, Inc. (ENVB)
NASDAQ: ENVB · Real-Time Price · USD
0.338
-0.017 (-4.66%)
At close: Jan 21, 2025, 4:00 PM
0.328
-0.009 (-2.76%)
After-hours: Jan 21, 2025, 7:47 PM EST
Enveric Biosciences Employees
Enveric Biosciences had 7 employees as of December 31, 2023. The number of employees decreased by 19 or -73.08% compared to the previous year.
Employees
7
Change (1Y)
-19
Growth (1Y)
-73.08%
Revenue / Employee
n/a
Profits / Employee
-$1,408,040
Market Cap
3.36M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7 | -19 | -73.08% |
Dec 31, 2022 | 26 | 2 | 8.33% |
Dec 31, 2021 | 24 | 21 | 700.00% |
Dec 31, 2020 | 3 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
ENVB News
- 15 days ago - Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025” - Business Wire
- 7 weeks ago - Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds - Business Wire
- 2 months ago - Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior - Business Wire
- 2 months ago - Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results - Business Wire
- 2 months ago - Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002 - Business Wire
- 2 months ago - Enveric Biosciences Announces Broad Range of Patent Issuances - Business Wire
- 3 months ago - Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003 - Business Wire
- 4 months ago - Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop - Business Wire